Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.76M | 1.22M | 1.24M | 1.09M | 1.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.70M | 5.27M | 6.05M | 5.53M | 4.53M |
| Operating Income | -5.70M | -5.27M | -6.05M | -5.53M | -4.53M |
| Income Before Tax | -5.53M | -5.65M | -6.40M | -6.01M | -5.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.53 | -5.65 | -6.40 | -6.01 | -5.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.53M | -5.65M | -6.40M | -6.01M | -5.00M |
| EBIT | -5.70M | -5.27M | -6.05M | -5.53M | -4.53M |
| EBITDA | -5.65M | -5.21M | -6.00M | -5.49M | -4.50M |
| EPS Basic | -1.14 | -1.27 | -1.45 | -1.37 | -1.15 |
| Normalized Basic EPS | -0.73 | -0.73 | -0.84 | -0.77 | -0.63 |
| EPS Diluted | -1.14 | -1.27 | -1.46 | -1.37 | -1.15 |
| Normalized Diluted EPS | -0.73 | -0.73 | -0.84 | -0.77 | -0.63 |
| Average Basic Shares Outstanding | 19.60M | 17.80M | 17.60M | 17.49M | 17.37M |
| Average Diluted Shares Outstanding | 19.60M | 17.80M | 17.60M | 17.49M | 17.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |